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Abstract
Androgen receptor (AR), is a transcription factor and a member of a hormone receptor superfamily. AR plays a vital role in
the progression of prostate cancer and is a crucial target for therapeutic interventions. While the majority of advanced-stage
prostate cancer patients will initially respond to the androgen deprivation, the disease often progresses to castrate-resistant
prostate cancer (CRPC). Interestingly, CRPC tumors continue to depend on hyperactive AR signaling and will respond to
potent second-line antiandrogen therapies, including bicalutamide (CASODEX®) and enzalutamide (XTANDI®). However,
the progression-free survival rate for the CRPC patients on antiandrogen therapies is only 8–19 months. Hence, there is a
need to understand the mechanisms underlying CRPC progression and eventual treatment resistance. Here, we have
leveraged next-generation sequencing and newly developed analytical methodologies to evaluate the role of AR signaling in
regulating the transcriptome of prostate cancer cells. The genomic and pharmacologic stimulation and inhibition of AR
activity demonstrates that AR regulates alternative splicing within cancer-relevant genes. Furthermore, by integrating
transcriptomic data from in vitro experiments and in prostate cancer patients, we found that a significant number of AR-
regulated splicing events are associated with tumor progression. For example, we found evidence for an inadvertent AR-
antagonist-mediated switch in IDH1 and PL2G2A isoform expression, which is associated with a decrease in overall survival
of patients. Mechanistically, we discovered that the epithelial-specific splicing regulators (ESRP1 and ESRP2), flank many
AR-regulated alternatively spliced exons. And, using 2D invasion assays, we show that the inhibition of ESRPs can suppress
AR-antagonist-driven tumor invasion. Our work provides evidence for a new mechanism by which AR alters the
transcriptome of prostate cancer cells by modulating alternative splicing. As such, our work has important implications for
CRPC progression and development of resistance to treatment with bicalutamide and enzalutamide.
Introduction
Androgen receptor (AR) is a member of the superfamily of
hormonal nuclear receptors [1]. In the absence of its ligand,
AR is secured in the cytoplasm by heat-shock proteins [2].
Once exposed to the male hormone androgen, AR, becomes
activated, and translocates to the nucleus, where it binds to
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the androgen response elements (ARE) and initiate the
transcriptional program [3–7]. Interestingly, activated AR
molecules both enhance and suppress the expression of
genes involved in prostate cancer progression [8–13]. This
hormone-driven AR signaling is essential for development,
differentiation, and normal functioning of the prostatic
gland [14]. AR signaling, however, is hijacked in prostate
tumors, driving disease progression. Therefore, the block-
age of AR signaling through androgen deprivation con-
tinues to be the mainstay treatment of advanced-stage
prostate cancer. While almost all patients with metastatic
disease will initially respond to androgen-ablation therapies,
the majority of patients will progress to a castrate-resistant
stage [15–18].
Interestingly, studies employing xenograft prostate tumor
models have shown that castrate-resistant prostate cancer
(CRPC) tumors that emerge after androgen-ablation ther-
apy, continue to express AR and AR-regulated genes [19].
Recent studies have argued that kinase-mediated hyper-
sensitivity of AR [20–24] and efficient uptake of androgens
may play a critical role in fueling CRPC tumors [25]. Thus,
the treatment option for patients with non-metastatic or
metastatic CRPC typically includes high-affinity anti-
androgens like bicalutamide (CASODEX®) and enzaluta-
mide (XTANDI®) [26–28]. Although in recent trials
enzalutamide has shown improved efficacy in comparison
to bicalutamide, the median time to PSA progression still
suggests a limited benefit that lasts no more than
8–19 months [29]. In addition, in a few cases, an increase in
metastasis of the disease was reported to be associated with
the AR-antagonist’s treatment regimen. Therefore, the
search for the mechanism underlying CRPC, CRPC pro-
gression, and eventual treatment resistance would benefit
patients who have exhausted all currently available treat-
ment options. Toward this effort, the comprehensive
understanding of AR functions continues to remain the
center of focus.
The recent advent of high-throughput RNA sequencing
and splicing microarrays has unveiled new layers of reg-
ulation of gene expression and highlighted the extreme
complexity and versatility of the transcriptome. The
majority of human genes encode multiple transcripts
through the use of alternative promoters, alternative splicing
(ASE), and alternative polyadenylation [30]. ASE is a
mechanism that significantly expands the functional
potential of the genome either by altering the usage of
protein-coding transcripts, the ratio of coding to noncoding
transcripts, or by allowing expression of isoforms with
antagonistic functions from a single gene [31]. Multiple
studies have found that ASE plays a critical role in cancer
[32]. A recent comprehensive analysis of ASE across 32
cancer types from 8705 patients revealed that tumors have
up to 30% more ASEs than normal tissues [33]. The steroid
nuclear hormone receptors, including estrogen and proges-
terone receptors, are known to recruit regulators of ASE and
modulate the transcriptome [34, 35]. However, whether
modulation of AR signaling may alter transcriptome of
prostate cancer cells via alternative splicing remains largely
unexplored.
Herein, we hypothesized that modulation of AR signal-
ing either during prostate cancer progression or in response
to treatment with AR antagonists might dysregulate the
transcriptome of prostate cancer cells by modulating ASE.
We employed a multitude of genomic approaches including
Affymetrix splicing array, whole transcriptome RNA-seq
analysis, and RT-PCR to show that AR signaling regulates
the transcriptome of prostate cancer cells by modulating
ASE of a wide array of genes involved in regulating protein
function. Furthermore, leveraging publicly available tran-
scriptome data of primary-site samples from patients with
prostate cancer at various stages of progression, we found a
subset of AR-driven splicing events that are associated with
progression of prostate cancer. Mechanistically, we found
that epithelial splicing regulator proteins (ESRP1 and
ESRP2) are the splicing factor through which AR may
regulate splicing of pre-mRNA in prostate cancer cells.
Interestingly, the inhibition of ESRPs suppressed AR-
antagonist-mediated increase in the invasion of prostate
cancer cells. Collectively, we provide the evidence for a
novel and critical mechanism of prostate cancer progression
that is regulated by AR and that the treatment with AR
antagonist may inadvertently promote invasion by dysre-
gulating splicing of critical genes. Our analytical approach
is described in Supplementary Fig. 1.
Pharmacological manipulation of AR
signaling induces alternative splicing in
prostate cancer cells
To study the effect of pharmacological manipulation of AR
signaling in prostate cancer cells, we performed expression
profiling of LNCaP cells that were cultured for 72 h in
charcoal-stripped fetal bovine serum and stimulated with
10-nM AR agonist, dihydrotestosterone (DHT), or 10 µM of
the AR-antagonist casodex for 24 h. The array consisted of
>6 million probes, of which 70% covered exons for coding
transcripts while the remaining 30% covered exon–exon
splice junctions and noncoding transcripts; hence, allowing
us to monitor transcriptional changes at the level of the
exon. Besides, the well-characterized gene expression
changes (Supplementary Table 1), we found that pharma-
cological manipulation of AR signaling induced global
changes in ASE, which was evident by differential
expression of exon–exon splice junction probes in com-
parison to constitutive exons (Supplementary Table 2).
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Figure 1a shows the expression of top-50 differentially
expressed probes spanning exon–exon junction of a gene
across different conditions. We next sought to characterize
the potential ASE events using the transcription analysis
console, which integrates the evidences from array probes
spanning exon–exon splice junction and constitutive exons
to classify the events as either cassette exon (CE), alter-
native 3 prime start site (A3SS), alternative 5 prime start
site (A5SS), intron retention (IR), complex event, alter-
native last exon (ALE), mutually exclusive exon (MEE), or
alternative first exon (AFE) (Fig. 1b). Because changes in
expression at gene level may confound changes at
exon–exon junction or intronic level, we filtered out any
splicing events that occurred within gene that were also
differentially expressed in summary, treatment of LNCaP
cells with DHT, or casodex resulted in 671 and 2127 sig-
nificant ASE events in comparison to DMSO treatment,
respectively. Furthermore, in comparison to stimulation,
inhibition of AR in LNCaP cells led to greater than 2827
ASE events. We found that treatment of LNCaP cells with
antagonist or agonist did not drastically alter the distribu-
tion of CE (63% vs. 84%), A3SS (12% vs. 6%), A5SS
(15.0% vs. 8.0%), ALE (0.2% vs. 0%), MEE (0% vs.
0.1%), and AFE (0.1% vs. 0%). However, treatment with
casodex did show a tenfold increase (11.0% vs. 1.0%) in
the percentage of IR events in comparison to agonist-
treated LNCaP cells.
We next sought to validate the ASE events predicted by
the splicing array using the RT-PCR assay. The CE and IR
are some of the most common splicing events contributing
toward transcriptional heterogeneity in tumor cells and are
also well-characterized [36–38, 33]. Therefore, we decided
to validate a total of 15 of these events in three separate cell
lines including LNCaP, 22RV1 (castrate-resistant prostate
adenocarcinoma cells), and PC3 (bone metastatic prostate
cancer cells). We performed three independent experiments
each with three technical replicates. The ASE events for
validation were picked based on the following three criteria:
(1) events with FDR cutoff of 0.05 and splicing index (SI)
of ≥|2|; (2) events with evidence from not only the probes
mapping to the alternatively spliced region but also those
that mapped to junction surrounding it; and (3) genes with a
known biological role in cancer. We used two primer pairs,
one for monitoring the expression of constitutive exons
within all the isoforms of a gene and another for measuring
changes in the alternatively spliced region (Supplementary
Table 3). The primers specific to the constitutive exons
revealed that LNCaP cells express 15 genes, 22RV1 express
13, and PC3 cells express 14 of 15 genes tested. The RT-
PCR assay validated 47%, 53%, and 28% of HTA-2.0
predicted splicing events in LNCaP, 22RV1, and PC3 cells,
respectively (Fig. 1c, Supplementary Figs. 2–4, and Sup-
plementary Table 4).
We next leveraged publicly available and in-house-
generated whole transcriptomic data to investigate whether
treatment with enzalutamide, a more potent AR antagonist
than casodex would also induce ASE in LNCaP cells.
Briefly, we performed strand-specific 150-bp paired-end
RNA-seq for LNCaP cells treated with vehicle or 10-nM
DHT. In addition, we downloaded a dataset for enzaluta-
mide or vehicle-treated LNCaP cells from GSE110903.
Altogether, we compiled data consisting of two biological
replicates per sample with 45–80 million mapped reads per
replicate. We used the rMATS computational pipeline with
default settings to identify the splicing changes. The ana-
lysis revealed that DHT and enzalutamide treatment
induced 198 and 167 significant ASE events, respectively,
at a stringent filter of FDR ≤ 0.05 and delta PSI of ≥10%.
The largest difference in ASE (~5663) was observed when
we compared the transcriptome of LNCaP treated with
enzalutamide with that of DHT (Fig. 1d). Furthermore,
rMATS classification of enzalutamide or DHT-induced
ASE revealed that the majority of splicing events were
either MEE or CE. The heatmap showing the top 100 sig-
nificantly different PSI for MEE and CE across LNCaP cells
treated with enzalutamide or DHT is shown in Supple-
mentary Fig. 5A. Moreover, splicing analysis using whole
transcriptome and splicing array data are reported to pro-
duce discordant results and consistent with that observation
we too found a very small overlap (377/4265) between
genes identified to undergo ASE upon treatment with
casodex or enzalutamide (Fig. 1e). Overall, evidence from
analysis of splice array, RT-PCR and whole transcriptome
data support our novel observation that modulation of AR
signaling alters transcriptome of prostate cancer cells by
regulating ASE.
Functional analysis of genes regulated at the
level of alternative splicing and transcription
in prostate cancer cells
In order to study the significance of ASE in prostate cancer
cells that are driven by pharmacological manipulation of
AR signaling, we first queried whether treatment with
enzalutamide or casodex altered splicing of prostate-cancer-
relevant genes. We curated a list of 100 genes (Supple-
mentary Table 5) that are associated with prostate cancer
progression and development. The HTA-2.0 analysis
showed 49 out of 100 prostate-cancer-relevant genes that
showed significantly (p ≤ 0.05) altered splicing in response
to casodex treatment of LNCaP cells. In addition, the
rMATS analysis showed that enzalutamide significantly
(p ≤ 0.05) induced splicing in 19 out of 100 prostate-cancer-
relevant genes. The heatmap comparing expression of dif-
ferentially expressed HTA probes spanning exon–exon
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junction of a prostate cancer genes and PSI of the prostate-
cancer-relevant genes across samples is shown in Fig. 2a.
Interestingly, a majority of alternatively spliced prostate-
cancer-relevant genes included key members of
PI3K–AKT–mTOR pathways, which included AKT2,
AKT3, GSK3β, PIK3R, PIK3CD, RB1, EGFR, PDGF,
MAPK3, KRAS, IDH1, and MTOR. IDH1 was one of the
RT-PCR-validated gene and is a key metabolic gene reg-
ulating TET2-mediated epigenetic re-programing in prostate
tumor cells [39, 40]. We found that casodex treatment of all
three prostate cancer cell lines resulted in a switch from
ENST00000345146, a dominant transcript of IDH1 to
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ENST00000415913 with an alternate 5′UTR (Supplemen-
tary Fig. 3). The translational relevance of this functional
switch was accentuated by our expression and survival
analyses, which revealed that the expression of the primary
isoform (ENST00000345146) is significantly higher (p=
1.84e− 43) in the TCGA-prostate adenocarcinoma tissue
(n= 495) in comparison to the GTEX-normal prostate tis-
sue (n= 100) and is also associated with decreased overall
patient survival (Fig. 2b).
We further investigated whether genes modulated by
casodex and DHT at the level of transcription and ASE have
different physiological roles. We derived biological roles
for this exclusive set of AR-axis modulated genes by using
gene ontology (GO) overrepresentation analysis. We used
all the genes that have an annotation as reference in our
analysis as recommended by clusterProfiler. The alter-
natively spliced genes were enriched in pathways related to
modulation of gene expression including nucleic acid,
protein transport, mRNA splicing, and proteosomal degra-
dation whereas the differentially expressed genes were
enriched in pathway related to EMT including those
involved in GTPase activity, cell–cell interaction/junctions,
and cytoskeleton organization (Fig. 2c). We next leveraged
RNA-seq data from enzalutamide and DHT-treated cells to
investigate the potential mechanisms of action through
which ASE may alter function of a gene. Briefly, we
mapped the region undergoing ASE to protein domains of
the gene using Maser R package. We found that the
majority of splicing occurred in the characterized functional
domains including the UniProt structural domains (domain),
transmembrane domain, coiled region, topo domain, metal
binding, zinc finger binding, and activation site for protein
(Supplementary Fig. 5B). Furthermore, similar to casodex,
enzalutamide treatment of LNCaP cells also dysregulated
splicing of genes enriched in pathways involved in the
modulation of gene expression including splicing, transport
of nucleic acid, proteasomal degradation, and protein
localization (Fig. 2d). Collectively, our results strongly
suggest that the changes in androgen-driven ASE are bio-
logically meaningful and distinct from the functional impact
of androgen-driven gene expression changes.
Direct genomic inhibition of AR in prostate
cancer cells induces alternative splicing
Our data provide evidence for the AR agonist- and
antagonist-mediated regulation of ASE of pre-mRNA.
However, it is possible that the observed ASE is a non-
specific effect from the pharmacological treatment of cells
and not a direct effect by modulation of AR. To test this
possibility, we modulated expression of AR in 22RV1 cells
using siRNA and used RT-PCR assays to study altered
splicing of genes including AAK1, SYNE4, and MAN1A1,
which were predicted to undergo ASE in response to
casodex treatment. We found a robust fivefold decrease in
the expression of AR in 22RV1 cells transfected with
siRNA in comparison to a scrambled siRNA (Fig. 3a).
Supporting our hypothesis, we found that the fivefold
inhibition of AR altered splicing of AAK1 (SI: −2.52),
SYNE4 (SI: −1.36), and MAN1A1 (SI: −3.22) in the same
direction as that of casodex (Fig. 3b and Supplementary
Table 4). This data support our hypothesis that ASE events
induced by agonists or antagonists of AR are driven in part
by direct modulation of AR.
We next leveraged publicly available (GSE110903)
RNA-seq data to further study the effects of genomic
inhibition of AR on ASE in MDA-PCa-2b cells, a model for
advanced prostate cancer (advPC) bone metastasis cells that
express PSA, AR, and are androgen sensitive. The rMATS
analysis revealed that siRNA knockdown of AR in MDA-
PCa-2b cells induced 3841 ASE events after a stringent
filtration of FDR ≤ 0.05 and delta PSI of ≥10%. Also,
similar to our observations with enzalutamide-treated
LNCaP cells, we found that the MEE formed the largest
fraction of ASE events induced by the siRNA knockdown
in MDA-PCa-2b and were followed by CE and IR events
(Fig. 3c). In addition, we used the upset plot for identifying
the overlap between genes that are regulated at the level of
splicing by the pharmacological inhibitors of AR in LNCaP
cells or genomic inhibition of AR in MDA-PCa-2b. We
found an overlap of 984 genes between enzalutamide-
treated LNCaP and siRNA-treated MDA-PCa-2b cells, 424
Fig. 1 Pharmacological inhibition of androgen receptor signaling
induces alternative splicing in prostate cancer cells. a Heatmap
showing the normalized probe intensity of top-50 differentially
expressed probes spanning exon–exon junction of a gene across dif-
ferent conditions including LNCaP cells cultured for 3 days in CSFBS
and treated with either vehicle (DMSO), 10-nM DHT, or 10-μM
casodex. b Bar plot detailing percentage of alternative-splicing events
including CE, A3SS, A5SS, IR, ALE, MEE, AFE, and complex events
in LNCaP cells across three comparisons including 10-nM DHT vs.
DMSO, 10-μM casodex vs. DMSO, and 10-μM casodex vs. 10-nM
DHT. c We leveraged RT-PCR and validated 15 splicing events,
which were rationally selected from the affy transcriptomic analysis in
three prostate cancer cell line models. Briefly LNCaP, 22RV1, and
PC3 cells were cultured in charcoal-stripped fetal bovine serum for
3 days and treated with either DMSO, 10-nM DHT, or 10-μM casodex.
The table details no. of genes tested, no. of genes expressed in each
cell line, and no. of genes that were validated using the RT-PCR assay.
d We leveraged in-house and publicly available data to interrogate
whether enzalutamide treatment modulates ASE in LNCaP cells in
comparison to DMSO or DHT treatment. Bar plot detailing percentage
of alternative-splicing events including CE, A3SS, A5SS, MEE, and
IR in LNCaP cells across three comparisons including DMSO vs.
DHT (within-study comparison), enzalutamide vs. DMSO (within-
study comparison), and enzalutamide vs. DHT (between study com-
parison). e Venn diagram comparing genes identified to undergo ASE
in LNCaP cells treated with either casodex or enzalutamide.
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genes between casodex and enzalutamide-treated LNCaP
cells, and 207 genes between casodex-treated LNCaP and
siRNA-treated MDA-PCa-2b cells. Interestingly, 323 genes
were common between all three treatment groups and were
enriched for pathways involved in the regulation of trans-
lation (Fig. 3d and Supplementary Fig. 5C). The plot also
Fig. 2 Functional analysis of genes regulated at the level of alter-
native splicing and transcription in prostate cancer cells. a Heat-
map showing the differential percent splice index (PSI) of prostate-
cancer-relevant genes between LNCaP cells cultured with 10-μM
casodex and 10-nM DHT. The adjacent heatmap shows the PSI across
different conditions including LNCaP cells treated with DHT or
enzalutamide. b Functional validation for the casodex-mediated switch
in the IDH1 isoform expression. The box plot comparing the
expression of the ENST00000345146 or ENST00000415913 between
TCGA-prostate adenocarcinoma tissue and GTEX-normal prostate
tissue. The Kaplan–Meier plot displays the association between
expression of ENST00000345146 and survival for patients with
prostate cancer. c A dot plot comparing GO pathways enriched in
differentially expressed or alternatively spliced genes modulated by
casodex and DHT. d A bar plot showing GO pathways enriched in
genes modulated by enzalutamide in comparison to DHT.
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revealed a nonoverlapping set of genes in all treatment
groups, possibly indicating a combination of differences in
prostate cell line models and assays used for measuring
ASE. The ASE genes also included known prostate-cancer-
relevant genes including CTNNB1, AKT1, LEF1, and VDR.
The heatmap comparing PSI for prostate cancer genes
across MDA-PCa-2b cells treated with scrambled or siRNA
against AR (Fig. 3e). Similar to enzalutamide-treated
LNCaP cells, the GO pathway analyses revealed that
genes undergoing ASE modulated by genomic inhibition of
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AR are enriched for pathways including mRNA splicing,
translation initiation, chromatin remodeling, epigenetic
regulation, and proteasomal degradation (Fig. 3f). In addi-
tion, the functional mapping of alternatively spliced exons
revealed that genomic inhibition of AR may dysregulate
function of the alternatively spliced genes by modifying
functional domains (Supplementary Fig. 5D). Overall, we
provide two lines of evidences supporting our hypothesis
that manipulation of AR-axis either by pharmacological
inhibitors of AR or by siRNA alters the splicing of pre-
mRNA, modifies the functional domain of gene, and con-
sequentially dysregulates its function.
AR-axis changes splicing of pre-mRNA by
modulating expression of ESRP1/ESRP2, the
master regulator of alternative splicing
RNA binding proteins (RBPs) are key proteins that bind to
mRNA or noncoding RNAs and play a wide variety of roles
in posttranscriptional processing including regulation of
ASE. Therefore, we hypothesized that RBPs, which are
differentially expressed in response to modulation of AR-
axis, might provide mechanistic insight into the observed
regulation of ASE. To test our hypothesis, we curated a list
of 112 RBPs from the published literature [41] with a
known role in splicing regulation and investigated whether
their expression was differentially regulated by treatment
with casodex or DHT in LNCaP cells. Interestingly, we
found that out of 112 RBPs only epithelial splicing reg-
ulator proteins (ESRP1/2) were significantly downregulated
(ESRP1: log2FC=−1.56; padj= 7.00e− 05; ESRP2:
log2FC=−4.91; padj= 5.46e− 07) in casodex-treated
LNCaP cells in comparison to DHT-treated cells (Fig. 4a
and Supplementary Table 1). We also leveraged STRING
database and identified that the nine key binding proteins of
ESRP1 and ESRP2 (protein-protein interaction enrichment
p value = 2.96e− 08) were deregulated by treatment with
casodex in comparison to DHT (Supplementary Fig. 5E).
ESRPs are reported to regulate splicing in a position-
dependent manner. Binding of ESRPs in the downstream
intron promotes exon inclusion, while binding within or
upstream from an exon promotes exon skipping [42].
Accordingly, we confirmed the enrichment of ESRP1/2
binding sites downstream from AR-enhanced CEs and
upstream from AR-excluded CEs in LNCaP cells treated
with enzalutamide. Figure 4b depicts enrichment of ESRP2
binding sites in the intronic region 0–125nt downstream of
AR-enhanced exons and underrepresented in the same
region downstream of AR-excluded exons. Interestingly,
we found that there is underrepresentation of ESRP1
binding sites in the intronic region 0–125nt downstream of
AR-enhanced exon and enrichment in the same region
downstream of AR-excluded exons. Furthermore, ESRP2
binding motifs were enriched upstream of AR-excluded
exons between −50 and −150 and underrepresented in the
same region of AR-enhanced exons. In contrast, ESRP1
binding motif were enriched upstream of the AR-enhanced
exons between 0 and −100 and underepresented in the
same region of AR-excluded exons. Also, ESRP2 motifs
were underrepresented in the region within the silenced and
upregulated exons, ESRP1 motif were enriched in the
upregulated exon and underrepresented in downregulated
exons. This suggests that pharmacological manipulation of
AR may alter splicing by regulating expression and binding
of ESRP1/2 around spliced exons. Consistent with our
findings, Munkley et al., recently published their findings
suggesting that androgen stimulation induces splicing
switches in ESRP2-controlled mRNA isoforms [43]. We
also inquired whether AR-axis may regulate splicing by a
nontranscriptional mechanism. For this we leveraged
STRING database and identified that out of 112 RBPs,
SART3 was predicted as a binding partner of AR with
string high confidence level of ≥0.7 (Supplementary Fig.
5F). Further supporting ESRP-independent mechanism of
action AR-axis driven ASE, we found SART3 to be enri-
ched downstream of AR-enhanced exons between 125 and
250 and underrepresented in the same region of AR-
excluded exons (Supplementary Fig. 5G).
ESRP1/2 is involved in EMT and invasion of cancer
cells [42, 44]. However, whether ESRP1/2 regulates EMT
or invasion of prostate cancer cells has not been estab-
lished. In order to study the significance of the AR-ESRP
axis in prostate cancer, we employed an in vitro invasion
assay. Consistent with published in vitro and in vivo
report [45], we found that treatment with DHT and caso-
dex increases the invasion rate of LNCAP and 22RV1
(Fig. 4c, d). Interestingly, when ESRP1/2 is silenced in
prostate cancer cells (Fig. 4e, f), the DHT- or casodex-
mediated increase in the invasion rate is completely
abolished. Furthermore, the genomic inhibition of ESRP1/
2 in prostate cancer cells did not affect the expression of
Fig. 3 Direct genomic inhibition of androgen receptor in prostate
cancer cells induces alternative splicing. Bar graph comparing
expression of AR in 22RV1 treated with scramble siRNA or siRNA
against AR. b Bar graph showing expression of AAK1, SYNE4, and
MAN1A1 in LNCaP cells treated with siRNA against AR in com-
parison to scramble siRNA. c Bar graph showing total number of
rMATS predicted splicing events in MDA-PCa-2b cells treated with
siRNA against AR or scrambled control. d Upset plot comparing the
genes predicted to undergo alternative splicing by rMATS or HTA-2.0
analysis in prostate cancer cells treated with casodex or enzalutamide
in comparison to DHT or siRNA against AR in comparison to
scrambled siRNA. e The heatmap comparing PSI for prostate cancer
genes across MDA-PCa-2b cells treated with scrambled or siRNA
against AR. f Bar graph revealing the GO pathway enriched for genes
under undergoing ASE modulated by genomic inhibition of AR in
MDA-PCa-2b.
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E-cadherin and vimentin, key genes involved in EMT
(Supplementary Fig. 6).
Modulation of AR-axis regulates splicing of
pre-mRNA that are associated with
progression of prostate cancer disease
Our analysis in prostate cancer cell lines shows that mod-
ulation of AR signaling dysregulates splicing of
functionally relevant genes. Since dysregulation of AR
signaling is the hallmark of prostate cancer progression, we
hypothesized that ASE of functionally relevant genes would
be associated with the progression of disease. To test our
hypothesis, we employed rMATS splicing analysis using
GSE80609 [46]. This dataset consisted of 8 benign prostate
hyperplasia (BPH), 16 localized prostate cancer (L.PC), 9
advPC, 12 CRPC, and 4 pairs of advPC and CRPC samples
from the same patient. Since the rate for RT-PCR validation
for bioinformatically predicted spliced events is low, we
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filtered our results with stringent cutoff of at least 10%
difference in PSI and minimum FDR value of at least 0.05.
In concordance with Kang et al. gene-centric study, our
splice analysis also found the greatest difference between
the transcriptome of BPH and L.PC and lowest between that
of advPC and CRPC (Fig. 5a). In particular, we found that
53 A3SS, 46 A5SS, 574 CE, 191 IR, and 277 MEE dif-
ferentiated BPH from L.PC (A); 25 A3SS, 13 A5SS, 155
CE, 81 IR, and 128 MEE events differentiated L.PC from
advPC (B); 8 A3SS, 10 A5SS, 73 CE, 20 IR, and 14 MEE
differentiated advPC from CRPC (C); and 10 A3SS, 20
A5SS, 72 CE, 37 IR, and 2 MEE differentiated paired
samples of advPC and CRPC (D) (Fig. 5a).
The earlier study identified dysregulation of AR
expression as the only shared event across all stages of
prostate cancer [46]. To the contrary, we found a total of
nine splice events to be associated with all stages of prostate
cancer (A∩B∩C∩D) (Supplementary Fig. 7A–C). These
events included CE and MEE in the pre-mRNA of cancer-
relevant genes, including TRIM37, PTGR1, CREM,
HMOX2, UPF3A, TNRC6B, PLA2G2A, and ESYT2. The
direction of PSI for these events varied during disease
progression, suggesting a differential role for these genes in
disease (Fig. 5b). Supplementary Fig. 7D–L shows the
transcript plots displaying the usage of exon for these nine
genes between AdvPC and CRPC. The transcriptome of
advPC and CRPC is reported to be highly similar and
previous study had identified only 15 genes that differ-
entiated their transcriptome. Hence, we further investigated
whether ASE events may further distinguish advPC from
CRPC. We compared the list of splicing events in paired
and unpaired samples of advPC and CRPC (C∩D) and
found 13 unique splicing events that differentiated the
transcriptome of advPC and CRPC (Supplementary Fig.
7A–C). These splicing events occurred in the pre-mRNA of
PTGR1, FRG1HP, RP11, CA5BP1, CREM, TNRC6B,
BCS1L, FASTKD1, ESYT2, CLN3, PLA2G2A, MYL6,
FBXL12, ZNF202, UBAP2, and MIR940 (Supplementary
Fig. 7M). The rMATS analysis of the prostate cancer
dataset identified that ASE is associated with tumorigenesis,
advanced progression, and CRPC development. Further-
more, in addition to differentially expressed genes, our
study identifies splicing events that can further differentiate
the transcriptome of advPC and CRPC.
Our analysis shows that pharmacological or genomic
inhibition of AR alters splicing of several functionally
relevant genes. Therefore, it is possible that a subset of
these alternatively spliced genes is associated with pro-
gression of prostate cancer. To test this possibility, we
compared the list of splicing events common across all
stages of prostate cancer (A∩B∩C∩D) and list of splicing
events induced by either pharmacological and genomic
inhibition of AR in LNCaP and MDA-PCa-2b cells
(Supplementary Fig. 7A–C). We found only one sig-
nificant event that alters the inclusion of exon-2
(Chr1:19979580-19979659) in the pre-mRNA of
PLA2G2A, a secreted phospholipase. PLA2G2A is sig-
nificantly downregulated in patients with metastatic pros-
tate cancer in comparison to the primary tumor. Moreover,
the decrease in expression of PLA2G2A is implicated in
promoting invasion and metastasis [47]. Interestingly,
exon-2 of PLA2G2A contains a repressor region, and its
inclusion is associated with a decrease in the expression of
the gene [48, 49]. In support of the known role of
PLA2G2A, we found an increase in the inclusion of exon-2
in advPC in comparison to CRPC (paired and unpaired
samples), BPH in comparison to L.PC (unpaired samples)
and in response to the pharmacological or genomic inhi-
bition of AR signaling in LNCaP and MDA-PCa-2b cell
lines, respectively (Fig. 5c).
To study the functional significance of the exon-2 spli-
cing, we performed expression and survival analysis with
the TCGA–PRAD and GTEX datasets. In particular, we
found that percentage of the ENST00000375111.7 isoform,
that contains exon-2 was significantly higher in patients
with prostate cancer (n= 496, TCGA-PRAD) in compar-
ison to healthy prostate tissue (n= 100, GTEX-prostate). In
contrast, the percentage of the ENST00000400520.7 iso-
form that does not contain exon-2 was significantly lower in
patients with prostate cancer in comparison to healthy
prostate (Fig. 5d). In addition, the survival analysis for
primary prostate cancer patients in TCGA dataset revealed
Fig. 4 Androgen receptor-axis changes splicing of pre-mRNA by
modulating expression of ESRP1/ESRP2, the master regulator of
alternative splicing. a Venn diagram showing an overlap between a
curated list of 112 RBPs with known role in regulating alternative
splicing, genes that were differentially expressed in LNCaP cells
treated with DHT or casodex in comparison to DMSO. b Maps for
ESRP1 and ESRP2 binding motifs showing enrichment upstream and
downstream from exons upregulated or downregulated in LNCaP cells
treated with enzalutamide in comparison to DHT. 2D invasion assay:
22 RVI c and LnCAP d cells were seeded on the Matrigel-coated
upper chamber of the transwell insert and treated with either vehicle
(DMSO) or with 10-nM DHT or 10-μM casodex in serum-free media,
while 10% FBS medium was added to the lower chamber used as
chemoattractant. After 24 h, migrated cells were fixed and stained with
crystal violet and counted using an inverted microscope. One-way
ANOVA test was performed using Prism 8 software. Data are
expressed as mean ± SEM; *P < 0.05, ******P < 0.00001. Experiment
was performed three times, with three replicates for each experiment.
22 RVI e and LnCAP f cells were transfected with indicated siRNA
cell, seeded on the Matrigel-coated upper chamber of the transwell
insert and treated with either vehicle (DMSO) or with 10-nM DHT or
10-μM casodex in serum-free media, while 10% FBS medium was
added to the lower chamber used as chemoattractant. After 24 h,
migrated cells were fixed and stained with crystal violet and counted
using an inverted microscope. One-way ANOVA test was performed
using Prism 8 software. Data are expressed as mean ± SEM; no sig-
nificand was detected. Experiment was performed three times, with
three replicates for each experiment.
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that patients with primary tumors with a higher difference
between percentage isoform of ENST00000375111.7 than
ENST00000400520.7 (>18.17; n= 122) had significantly
(p= 0.021) shorter overall survival compared to those dif-
ference of <4.08 (n= 123) (Fig. 5e). In conclusion, we
show that differential usage of exon or introns is associated
with progression of prostate cancer. In addition, inhibition
of AR may inadvertently switch the delicate balance
between different splice isoforms in genes critical for dis-
ease progression.
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Discussion
In this study, we leveraged a combination of next-
generation sequencing and molecular methodologies to
provide critical pieces of evidence for a direct role of AR
and its clinical inhibitors in regulating the transcriptome of
prostate cancer cells by modulating global alternative spli-
cing. A key finding from our study is that AR-driven
alternatively spliced genes had a distinct physiological role
from those that were transcriptionally regulated by AR in
prostate cancer cells. Furthermore, we found that anti-
androgens currently used in clinics may inadvertently con-
tribute to the disease’s progression by dysregulating
splicing. Given that prostate cancer patients on antiandro-
gens will only experience 8–19 months of progression-free
survival [29], our study provides one possible explanation
for disease progression on these therapies.
ASE is known to play a significant role in maintaining
cellular physiology. Therefore, identifying the transcrip-
tional splicing patterns may have the potential for early
diagnosis, prognosis, and identification of therapeutic tar-
gets in tumor biology [50]. The nuclear hormone receptors,
including estrogen and progesterone receptors, are known to
modulate ASE. However, the role of AR in modulating
ASE remains mostly unexplored. Munkley et al. recently
used the genomic knockdown of ESRPs to identify global
splicing changes associated with ESRPs in prostate cancer
cells. They also found that a subset of ESRP1/2 regulated
exons were also regulated by androgen treatment [43].
However, the study did not address whether or not AR-axis
induces global splicing changes in prostate cancer cells
beyond those regulated by ESRPs. Therefore, there remains
a gap in our understanding of AR signaling and if it can
regulate the transcriptome of prostate cancer cells by
altering global splicing levels. In this study we focused on
whether genomic and pharmacological inhibition of AR
expression and AR activity, respectively, could regulate
global ASE in prostate cancer cells. We also explored
prognostic and functional implications of splicing induced
by genomic and pharmacological manipulation of AR cur-
rently used in the clinic.
We leveraged HTA-2.0, a newer generation of micro-
array that interrogates junctions between exons in the
transcriptome as well as the exon themselves and RNA-Seq
analysis to test whether modulating AR signaling would
alter ASE prostate cancer cells. This approach leds to an
unexpected finding that treatment with DHT or casodex
induces a large number of ASE in prostate cancer cells. We
confirmed our observations by conducting a thorough
validation of predicted splice events using real-time PCR in
three different prostate cancer cell lines, including
androgen-sensitive LNCaP, castrate-resistant 22RV1, and
metastatic PC3 cell lines. We also leveraged in-house and
publicly available RNA-Seq data to validate whether inhi-
biting AR signaling with enzalutamide would also induce
ASE. Indeed, our analysis found that enzalutamide in
comparison to DMSO control induced ASE in LNCaP cells.
Similar to casodex experiment, the highest number of ASE
was observed when a comparison was made between
enzalutamide- and DHT-treated LNCaP cells. However, a
comparison between DHT- and enzalutamide-treated
LNCaP cells involves comparing experiments from differ-
ent groups; therefore, we cannot rule out the possibility of a
batch effect in this comparison. Given the limitations of
across study comparison, we also performed a within study
comparison between LNCaP cell treated enzalutamide and
DMSO. Supporting our hypothesis that treatment with AR
signaling modulates alternative splicing, we found that
enzalutamide induced >150 ASE in comparison to DMSO
treated LNCaP cells. Further experiments would be needed
to validate observed changes between DHT- and
enzalutamide-treated prostate cancer cells. In conclusion,
we leveraged in vitro experiments and publicly available
genomic data to support our findings that AR signaling may
alter the transcriptome of prostate cancer cells by mod-
ulating global ASE.
AR molecules in the cytoplasm dimerize and translocate
to the nucleus in response to androgens. Dimerized mole-
cule of AR binds to ARE and regulates target gene
expression. Therefore, a majority of published reports have
primarily focused on genes transcriptionally regulated by
AR to understand the physiological significance of AR
signaling. Consequently, we tested whether the AR-
signaling-regulated ASE has a different physiological role
from differentially expressed genes. Consistent with earlier
findings, we found that inhibiting AR signaling leds to
expression changes of genes involved in EMT [51, 52].
However, contrary to the report from Munkley et al., which
proposed that AR may regulate splicing of essential EMT
Fig. 5 Modulation of AR-axis regulates splicing of pre-mRNA that
is associated with progression of prostate cancer disease. a Bar
graph comparing significant number of splicing events across patients
at different stages of prostate cancer including benign prostate
hyperplasia (BPH), localized prostate cancer (L.PC), advanced pros-
tate cancer (advPC), castrate-resistant prostate cancer (CRPC), and
four pairs of advPC and CRPC samples from the same patient. b
Heatmap comparing the PSI for the cassette or mutually exclusive
exons across patients at different stages of prostate cancer. c Box plot
displaying the changes in PSI of the exon-2 of PLA2G2A gene in
patients at different stages of prostate cancer or in prostate cancer cells
treated with DMSO, DHT, Enzalutamide, scrambled siRNA, or siRNA
against AR. d The box plot comparing the expression of the
ENST00000375111.7 or ENST00000400520.7 between TCGA-
prostate adenocarcinoma tissue and GTEX-normal prostate tissue. e
The Kaplan–Meier plot displays the association between overall sur-
vival for patients with prostate cancer and difference in expression of
percentage isoform of ENST00000375111.7 than
ENST00000400520.7.
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related genes, we did not find AR-axis-driven ASE enriched
for EMT-associated pathways. Instead, we discovered that
AR-axis-driven ASE were enriched in pathways involving
gene expression regulation, nucleic acid and protein trans-
port, mRNA splicing, and proteasomal degradation. The
differences observed could be driven by the fact that while
previous work focused on the genomic knockdown of
ESRPs, our work exclusively focused on modulating AR
expression or its activity to identify AR-axis-driven ASE
events. Because we filtered out alternatively spliced genes,
which were also differentially expressed, we were able to
discover a new and unique physiological impact of mod-
ulating AR signaling in prostate cancer cells. The role of
AR-regulated splicing is further signified by our analysis
showing that the majority of splicing occurred in char-
acterized functional domains, including the transmembrane
domain, coiled region, topo domain, metal binding, zinc
finger binding, and activation sites. The lack of overlapping
functional role between differentially expressed and ASE
could be explained by the fact that we had excluded ASE
occurring in genes that were also regulated transcriptionally.
Interestingly, we observed that inhibiting AR signaling
using casodex and enzalutamide significantly increased IR
compared to DHT treatment. IR is known to generate
abnormal transcripts that are translated into immunogenic
peptides, loaded on MHC-1, and presented to the immune
system [53]. Therefore, patients with advanced-stage pros-
tate cancer undergoing treatment with AR inhibitors may
have a higher neoepitope load and hence benefit from
immune checkpoint inhibitors. Further studies will be
necessary to predict and validate the immunogenicity of
neoepitopes generated in response to AR inhibitors,
including identification of T cells infiltrating prostate
tumors specific to predicted neoepitopes.
The results from our work suggest that AR agonists and
antagonists may dysregulate ASE within the pre-mRNA of
genes that regulate tumor biology. Because pharmacologi-
cal modulators may have nonspecific activity, it is possible
that the observed ASE observed in response to treatment
with AR modulators is not mediated through AR. There-
fore, using RT-PCR we demonstrated that genomic inhibi-
tion and pharmacological inhibition of AR may induce
similar splicing pattern, within a subset of genes in prostate
cancer cells. In addition, we also found a significant overlap
as well as unique ASE events induced in different prostate
cancer cells treated by pharmacological inhibitor or the
genomic inhibition of AR. For our global splicing analysis,
we leveraged multiple prostate cancer cell lines; therefore,
some of the common or unique ASE events identified could
be because of cell line differences and not an effect of
treatment. Therefore, the global comparison of ASE
between the pharmacological inhibitor and genomic inhi-
bition of AR signaling in prostate cancer cell lines needs
further validation. Also, we may not be able to rule out the
possibility of nonspecific pathways being engaged by
pharmacological inhibitors of AR to dysregulate splicing.
However, based on analytical models that predict splicing in
response to genomic and pharmacological inhibition and
RT-PCR validation provides sufficient evidence to conclude
that ASE events induced in response to treatment with AR
inhibitor are in parts driven by direct modulation of AR
expression.
The regulation of ASE is primarily mediated by RBPs
that interact with sequences flanking exon and introns as
splicing enhancers or silencers, depending on the regulator
and binding context. Because AR is a transcription factor,
we argued that AR might regulate ASE by transcriptionally
regulating the expression of RBPs. We tested 112 well-
characterized RBPs and found that expression of ESRP1/2
in prostate cancer cells decreased in response to treatment
by pharmacological inhibitors of AR. Interestingly,
expression of proteins predicted to bind with ESRP1/2 was
also deregulated by inhibition of AR signaling. We further
confirmed that ESRP1/2 binding sites were enriched
downstream from AR-enhanced CEs and upstream from
AR-excluded CEs in response to pharmacological inhibition
of AR in LNCaP cells. In support of our findings, Munkley
et al. also reported that AR controls expression of ESRPs to
regulate ASE in prostate cancer cells. However, contrary to
the model proposed, we show that the AR-ESRP axis may
be only of the mechanisms by which AR may regulate
splicing events. To that extent, we found that the SART3, a
RNA binding protein and a binding partner of AR, was
predicted to be enriched downstream of AR-enhanced
exons and underrepresented in the same region of AR-
excluded exons in prostate cancer cells. The prediction of
AR-SART3 axis being involved in regulating subset of ASE
in prostate cancer cells suggests that AR may employ
multiple mechanisms to modulate global splicing and they
need to be carefully investigated. We will need to perform
ChIP-Seq to directly validate whether androgens or anti-
androgens dysregulate ESRP and SART3 binding around
AR-axis driven CEs. Also, it would be interesting to study
whether AR and ESRP or SART3 bind within the same
region and are part of a protein complex regulating splicing.
Because ESRP plays a critical role in EMT and tumor
invasion in several tumor types [44], we hypothesized that
the AR-ESRP axis might be critical for promoting metas-
tasis either by promoting EMT or promoting invasion.
Moreover, although pharmacological inhibitors of AR-
signaling suppress tumor growth, we and others have shown
using in vitro and in vivo approaches that it also promotes
invasion of tumor cells [45]. Hence, it is critical to identify
new therapeutic targets that may alleviate accidental inva-
sion promoting effects of inhibiting AR signaling in
advanced state prostate cancer. Our in vitro invasion assay
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found that silencing ESRP protein abrogates casodex-
mediated increase in the invasion of prostate cancer cell
lines. ESRPs are reported to be involved in EMT. There-
fore, we analyzed E-cadherin and Vimentin, which are
among the most prominent markers involved in EMT and
have found no detectable differences in their expression in
response to treatment with siRNA against ESRP1/2. This is
contrary to the model proposed by Munkley et al., which
hypothesized that downregulation of ESRP2 may decrease
epithelial splicing pattern and prime prostate cancer cells for
future development of mesenchymal phenotype. However,
Munkley et al. did not assess whether genomic knockdown
of ESRP1/2 resulted in changes in EMT marker genes (E-
cadherin or Vimentin) in prostate cancer cells. Conversely,
they did not find any significant association between
increase in expression of ESRP1/2 in prostate carcinoma
and E-cadherin levels. It is possible that more evident sign
of the activation of EMT may be visible in our assay after a
longer period of incubation as reported by previously
published evidence using the same cell lines in which EMT
was analyzed after 48 or 72 h [54, 55]. However, to be
consistent with the invasion assay time frame, we analyzed
cells 24 h after treatment. Based on findings from our study,
ESRPs as a therapeutic target in combination with AR
inhibitors may warrant further investigation as it provides a
potential approach to counter the invasive phenotype acci-
dentally promoted by treatment with AR inhibitors.
Our work using prostate cancer cell lines showed that
AR signaling dysregulates the splicing of functionally
relevant genes. Because AR signaling is a hallmark of
prostate cancer progression, we also investigated whether
AR-regulated ASE is associated with the progression of
disease. Our analysis showed that significant splicing events
are occurring during different stages of prostate cancer
progression. Contrary to an earlier study [46], which had
found that dysregulation of the expression of AR was the
only event associated with all stages of prostate cancer, we
found an additional nine splicing events. Therefore, our
work also reveals a new potential area of inquiry into the
underlying biology of prostate cancer initiation and pro-
gression to the castrate-resistant stage.
Furthermore, the transcriptomic analysis had only identified
15 genes that were differentially expressed between advPC
and CRPC, thus making these two stages of prostate cancer
challenging to differentiate. By focusing on ASE, we have
now identified an additional 13 genes that are differentially
spliced between advPC and CRPC. Thus, a combined gene
expression and splicing panel could potentially have a higher
diagnostic value to discriminate patients in an advanced stage
from the one with the castrate-resistant disease.
Lastly, we investigated whether the treatment of pros-
tate cancer cells with pharmacological inhibitor enzalu-
tamide may lead to an inadvertent switch in the splicing of
a pre-mRNA and promote tumor progression. Our ana-
lysis found that dysregulation of AR signaling in prostate
cancer driven by enzalutamide treatment increases the
inclusion of exon-2 of the PLA2G2A gene in prostate
cancer cells. The translational significance of the inclusion
of exon-2 was validated in the TCGA-PRAD, where we
revealed that the PLA2G2A isoform that includes exon-2
is a prognostic factor for outcomes, providing strong
evidence for developing a therapeutic strategy that can
mitigate the inadvertent pro-tumorigenic effects of inhi-
biting AR signaling.
In conclusion, this study highlights the so-far unde-
scribed role of AR in modulating gene expression via ASE
in prostate cancer. This discovery also opens a new ther-
apeutic path and supports the rationale for using ESRP
modulators in combination with AR antagonists for the
treatment of advanced-stage prostate cancer to counteract
the AR-antagonist-driven invasive phenotype.
Materials and methods
Reagents
5α-DHT, casodex, and Enzalutamide were obtained from
Sigma and were resuspended in DMSO (Sigma). Primers
were designed manually and were purchased from Inte-
grated DNA Technologies. Anti-ESRP1 (#21045-111-AP)
and anti-ESRP2 (#23317-1-AP) were obtained from the
Proteintech. E-Cadherin (4A2) (#14472) and Vimentin
(D21He) (#5741) were obtained from the CellSignaling,
while anti-aTubulin antibody (#A01410) was obtained from
Genscript. All other reagents if not specified were obtained
from Thermo fisher Scientific.
Cell culture
The human cell lines LNCaP (androgen-sensitive human
prostate adenocarcinoma cells) and 22RV1 (human pros-
tate carcinoma epithelial cell line derived from a xenograft
that was serially propagated in mice after castration-
induced regression and relapse of the parental, androgen-
dependent CWR22 xenograft) were obtained from ATCC
and were cultured in RPMI-1640 medium. PC3 (metastatic
prostate cancer cells isolated from bones, ATCC) was
maintained in F-12K medium. All culture medium was
supplemented with 10% HyClone Defined Fetal Bovine
Serum (GE Healthcare) and 1% Pen/Strep (Invitrogen)
unless specified. Cell cultures were tested every 6 months
for cross-contamination using human STR profiling cell
authentication service provided by ATCC. Mycoplasma
contamination was tested using MycoAlert Mycoplasma
Detection Kit (Lonza).
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Western blotting
Cells were dissolved in RIPA buffer (sigma). Protein con-
centration was measured by BCA protein assay reagent kit
(Pierce, Rockford, IL, USA), as described previously. Pro-
teins were fractionated on 10% SDS-PAGE, and transferred
by electrophoresis to nitrocellulose transfer membrane
(GE). Membranes were incubated with primary antibodies
for overnight. Horseradish peroxidase-conjugated antibody
anti-mouse IgG and anti-rabbit IgG (Dako) were used to
detect immunoreactive bands and binding was revealed
using enhanced chemiluminescence (Pierce). The blots were
then stripped and used for further blotting for control anti-
body. Unless otherwise specified, displayed western blots
are representative images of at least two independent
experiments.
siRNA transfection
22RV1 cells were transfected with a mixture of four dif-
ferent siRNA targeting AR (siRNA #L-003400-00-0010)
and non-targeting control pool (#D-001810-10-05). PC3,
LNCaP, and 22RV1 cells were transfected with a mixture of
four different siRNA targeting ESRP1/ESRP2 kinases and
negative control (SiGenome ESPR1 #D-020672-01, On-
Target ESPR2 #J-014523-05, Darmacon, and Silencer
Negative control, #4390843 Thermo fisher). Cancer cells
were seeded in a six-well plate. 200-nM siRNA/well were
used for transfection using 5 µl/well of Hi-Perfect (Qiagen)
following manufacturer’s recommendation.
2D invasion assay
Reduced growth factors Matrigel (BD Biosciences) was
polymerized in 8-mm pore cell inserts (Sarstedt) prior to
the addition of cells. LNCaP and 22RV1 (5 × 106 cells)
were seeded into the insert containing Matrigel in serum-
free media. Twenty percent FBS medium was used as an
attractant in the bottom chamber, and cells were allowed
to migrate for additional 24 h. The inserts were removed,
and migrated cells were fixed with 4% paraformaldehyde
and stained with crystal violet. The inserts were then
imaged, and migrated cells were counted, hence, provid-
ing a quantitative value for migrated cells across the
membrane.
Human transcriptomic array
LNCaP cells were cultured for 3 days in the RPMI-1640
with 10% charcoal-stripped fetal bovine serum and treated
with either 10-nM DHT, 10-µM casodex, or DMSO for
24 h. Total RNA was extracted using the RNeasy mini kit
(Qiagen) and quantified using Nanodrop ND-100
Spectrophotometer (Thermo Fisher Scientific). The quality
of RNA was assessed using Agilent 2100 Bioanalyzer
(Agilent). Biotinylated cDNAs were prepared from a
minimal 100 ng of total RNA using Life Technologies WT-
plus RNA Amplification system (Ambion). Following the
amplification, cDNA was fragmented, hybridized on Affy-
metrix GeneChip Human Transcriptome Array 2.0 (HTA-
2.0) chips, and nonspecific bindings were washed as per
manufacturer’s recommendations. The fluorescence inten-
sity of the arrays was scanned using the Affymetrix Scanner
and the raw data. The raw data were analyzed using the
Transcriptome Console Software (TAC 2.0) that allows for
the identification of differentially expressed genes and
leverages information from the junction and exons probes to
detect ASEs and possible transcript isoforms that may exist
in samples.
For microarray data analysis, two parallel analysis
(gene-level and alternative-splicing level) were performed
using HTA-2.0. Data were normalized using quantile
normalization and the background was detected using the
built-in detection above background algorithm (DABG).
Only the probesets that were characterized by a DABG
p value < 0.05 in at least 50% of the samples were con-
sidered as statistically significant. Principal component
analysis was used to calculate variance and confirm if the
variance is similar between the groups being compared.
Genes were considered to be differentially expressed
when fold change (FC), log ≤−2.0 or ≥+2.0 and FDR
corrected p value ≤ 0.05. The splicing level analysis as
also carried out using TAC 2.0 software, which deter-
mines the SI of a gene. The SI corresponds to a com-
parison of gene-normalized exon-intensity values between
the two analyzed experimental conditions. Additional
criteria used besides SI: FDR corrected p value ≤0.05, a
gene is expressed in both conditions tested, a probeset
ration (PSR)/junction must be expressed in at least one
condition, a gene must contain at least one PSR value, and
a gene cannot be differentially expressed.
Reverse transcription PCR validation for splicing
events
A total validation of 15 splicing events was performed on
three prostate cancer cell lines including LNCaP, 22RV1,
and PC3 at various disease state (primary prostate cancer,
castrate-resistant, and metastatic prostate cancer). Briefly,
the prostate cancer cells were cultured for 3 days in 10%
CSFBS and were treated with either DMSO, 10-nM DHT,
or 10-µM casodex for 24 h. Total RNA was extracted, and
cDNA was prepared using SuperScript IV First-Strand
Synthesis System (Thermo Fisher Scientific). cDNA sam-
ples were amplified using SYBR® Green PCR Master Mix
on the Applied Biosystems 7500 Detection System.
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Spicing-specific primers included two primer pairs, one for
monitoring the expression of constitutive exons within all
the isoforms of a gene and another for measuring changes in
the alternatively spliced region. Furthermore, specificity and
efficiency for primers were analyzed by running RT-PCR
with series of cDNA dilutions, and specific amplification for
every assay was confirmed by melt curve analysis. The
amplified transcripts were quantified using the comparative
ΔΔCt method. GAPDH and HPRT were used as the
internal control. SI was calculated for (A) by normalizing
FC to the average FC of (C) for each splicing event. All
assays were run in triplicates and were repeated three times.
A raw Ct of 35 is used as the limit of detection: Ct values
are set at 35 for any replicates with Ct values not deter-
mined or >35.
Raw data processing, alignment analysis, and
identification of differentially expressed genes and
ASEs
High-quality RNA samples were extracted, and illumine
library was constructed as described earlier. Libraries were
pooled and diluted for sequencing with a 1% PhiX spike-in
according to Illumina protocol. The pool of library was
loaded onto the HiSeq was performed using a 300-cycle
high output v2 kit. Reads were obtained from sequencer or
were downloaded from GEO. Adapter sequences and
invalid reads containing poly-N and low-quality were
removed using the FastX tool kit (v 0.0.14). The quality of
reads was then confirmed using fastqc tool kit (v 0.11.5).
All downstream analysis used the cleaned reads. The clean
reads were mapped to the ENSEMBL built GRC38 using
the STAR aligner (v2.5.3a) using ENCODE option as
described in the STAR manual. Principal component ana-
lysis was performed to calculate variance within each
group, and differential expression of genes was obtained
using the DESeq2 (v1.28.0) (https://bioconductor.org/packa
ges/release/bioc/html/DESeq2.html) method as described
earlier [56]. Subsequently, we used rMATS (version3.0.8)
(http://rnaseq-mats.sourceforge.net) to identify differentially
ASE between the two sample groups. Briefly, rMATS uses
a modified version of the generalized linear mixed model to
detect differentially ASE from RNA-Seq data with repli-
cates, while controlling for changes in expression at gene
level. In addition, it also accounts for exon-specific
sequencing coverage in individual samples as well as var-
iation in exon splicing levels among replicates. rMATS was
run using the default parameters and then significant spli-
cing events were filtered using a stringent cutoff of FDR ≤
0.05 and delta PSI ≥ 10%. The Maser (v1.6.0) https://www.
bioconductor.org/packages/release/bioc/html/maser.html
was used for extracting and visualizing splice events.
Motif enrichment analysis
We employed rMAPS2 (http://rmaps.cecsresearch.org)
analysis to determine the binding patterns of splicing factors
and RNA binding proteins within significantly detected
exon skipping ASE between two treatment groups. We
collected well-characterized 115 known binding sites of
RNA binding proteins. For each motif, the analysis scanned
for motif occurrences separately in exons or their 250-bp
upstream or downstream intronic sequences. Furthermore,
for the intronic sequences our analysis excluded the 20-bp
sequences within the 3′ splice site and the 6-bp sequences
within the 5′ splice site. In addition, by default the alter-
native exons without splicing changes as defined by rMATS
FDR > 50%, maxPSI > 15%, and minPSI < 85% were trea-
ted as control exons. For each motif tested, the analysis
counted the number of occurrences and motif score in the
upstream exon, upstream flanking intron, target exon,
downstream flanking intron, and downstream exon sepa-
rately. The p value for motif enrichment was calculated
using the Wilcoxon’s rank sum test for each sliding window
between upregulated versus control or downregulated ver-
sus control exons.
Functional annotation of DEGs and ASE
ReactomePA (v1.32.0) and the clusterProfiler (v3.16.0)
were used to generate lists of the GO terms enriched in the
DEGs and ASE. The integration of protein features to
splicing events was carried out using maser package.
Briefly, maser enables systematic mapping of protein
annotation from UniprotKB to splicing events and deter-
mine whether the splicing is affection regions of interest
containing known domains or motifs, mutations, post-
translational modification, and other described protein
structural features.
Data availability
Microarray Data: GSE150475.RNA-seq Data:
SUB7404248.
Code availability
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